The Frequent Hemodialysis Network Daily Trial randomized 245 patients to receive six (frequent) or three (conventional) in-center hemodialysis sessions per week for 12 months. As reported previously, frequent incenter hemodialysis yielded favorable effects on the coprimary composite outcomes of death or change in left ventricular mass and death or change in self-reported physical health. Here, we determined the long-term effects of the 12-month frequent in-center hemodialysis intervention. We determined the vital status of patients over a median of 3.6 years (10%-90% range, 1.5-5.3 years) after randomization. Using an intention to treat analysis, we compared the mortality hazard in randomized groups. In a subset of patients from both groups, we reassessed left ventricular mass and self-reported physical health a year or more after completion of the intervention; 20 of 125 patients (16%) randomized to frequent hemodialysis died during the combined trial and post-trial observation periods in contrast to 34 of 120 patients (28%) randomized to conventional hemodialysis. The relative mortality hazard for frequent versus conventional hemodialysis was 0.54 (95% confidence interval, 0.31 to 0.93); with censoring of time after kidney transplantation, the relative hazard was 0.56 (95% confidence interval, 0.32 to 0.99). Bayesian analysis suggested a relatively high probability of clinically significant benefit and a very low probability of harm with frequent hemodialysis. In conclusion, a 12-month frequent in-center hemodialysis intervention significantly reduced long-term mortality, suggesting that frequent hemodialysis may benefit selected patients with ESRD. Nearly 400,000 persons in the United States and .2 million worldwide are dialysis dependent; of these, .90% in the United States and 70% in Canada receive hemodialysis, typically delivered thrice weekly. 1 Mortality rates in the hemodialysis population remain high (approximately 15%-20% per year overall and .30% in patients over 65 years old), 1 and health-related quality of life (HRQoL) for most patients is quite poor. 2 A large randomized clinical trial (the Hemodialysis Study) compared high-dose versus conventional-dose thrice weekly hemodialysis (target equilibrated Kt/V urea [eKt/ V urea ] of 1.45 versus 1.05) and showed no benefit on mortality, cardiovascular events, or HRQoL. 3,4 Small, uncontrolled studies showed that patients treated with frequent hemodialysis enjoyed favorable changes in multiple biochemical parameters, improved control of hypertension, and in many studies, improved HRQoL. 5-8 These preliminary results justified and informed the design and implementation of the Frequent Hemodialysis Network (FHN) randomized clinical trials. 9 Given the expense of frequent hemodialysis and other feasibility concerns, we chose to examine an array of intermediate outcomes measured at baseline and